T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
World game at war: why some European nations have threatened a World Cup boycott 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
EMERYVILLE, Calif., April 11, 2018 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, Gail Farfel, Ph.D., Executive Vice President and Chief Development Officer, and Michael P. Smith, Executive Vice President, Chief Financial Officer, Treasurer and Secretary, will provide a corporate update at the LEERINK Partners CNS Day, being held in New York City on April 18, 2018.
LEERINK Partners CNS Day – Zogenix Presentation Details
Date: Wednesday, April 18, 2018
Time: 2:40 pm Eastern Time / 11:40 am Pacific Time
Location: New York, NY - Convene Conference Center
The presentation will be webcast live and archived for 90 days on Zogenix's Investor Relations website at www.ir.zogenix.com.
About Zogenix
Zogenix, Inc. (NASDAQ:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT:
Investors:
Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987
[email protected]
